Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future

被引：0
作者：
Rajappan, Kim [1 ]
机构：
[1] John Radcliffe Hosp, Dept Cardiac, Oxford OX3 9DU, England
来源：
HEART | 2013年 / 99卷 / 06期
关键词：
RISK; WARFARIN;
D O I：
10.1136/heartjnl-2012-302762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：361 / 362
页数：2
相关论文
共 14 条
  • [11] A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
    Pisters, Ron
    Lane, Deirdre A.
    Nieuwlaat, Robby
    de Vos, Cees B.
    Crijns, Harry J. G. M.
    Lip, Gregory Y. H.
    [J]. CHEST, 2010, 138 (05) : 1093 - 1100
  • [12] Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients
    Sellers, Matthew B.
    Newby, L. Kristin
    [J]. AMERICAN HEART JOURNAL, 2011, 161 (02) : 241 - 246
  • [13] Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation - An individual patient meta-analysis
    van Walraven, C
    Hart, RG
    Singer, DE
    Laupacis, A
    Connolly, S
    Petersen, P
    Koudstaal, PJ
    Chang, YC
    Hellemons, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19): : 2441 - 2448
  • [14] Impact of atrial fibrillation on mortality, stroke, and medical costs
    Wolf, PA
    Mitchell, JB
    Baker, CS
    Kannel, WB
    D'Agostino, RB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (03) : 229 - 234
12